Predicting survival in chronic lymphocytic leukemia

Expert Review of Anticancer Therapy

Volumn 12, Issue 3, 2012, Pages 393-403

  Bazargan, Ali ^a   Tam, Constantine S ^a   Keating, Michael J ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cytogenetics; FISH; fludarabine; IgVH; prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; MONOCLONAL ANTIBODY; PROTEIN KINASE ZAP 70; RITUXIMAB; THYMIDINE KINASE; TUMOR MARKER;

ANTIGEN EXPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER INVASION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE MARKER; GENE DELETION; HUMAN; IGVH GENE; KARYOTYPING; LYMPHOCYTE TRANSFORMATION; MARKER GENE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TP53 GENE; TUMOR GENE; TUMOR GROWTH;

ABNORMAL KARYOTYPE; BETA 2-MICROGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOLOGIC FACTORS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MEDICATION THERAPY MANAGEMENT; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OLIGODEOXYRIBONUCLEOTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; THYMIDINE KINASE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857854941     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.2     Document Type: Review

References (99)

1. Keating MJ, O'Brien S, Kontoyiannis D et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma 43, 1755-1762 (2002).
2. Mauro FR, Foa R, Giannarelli D et al. Clinical characteristics and outcome of young chronic lymphocytic patients: A single institution study of 204 cases. Blood 94, 448-454 (1999).
3. Thurmes P, Call T, Slager S et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk. Lymphoma 49, 49-56 (2008).
4. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood 46, 219-234 (1975).
5. Tam CS, O'Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112, 975-980 (2008).
6. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
7. Byrd JC, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105, 49-53 (2005).
8. Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109, 405-411 (2007).
9. Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within arandomized multicenter Phase 3 trial of the German CLL study group (GCLLSG). Leukemia 18, 1093-1101 (2004).
10. Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 23, 2971-2979 (2005).
11. Bosch F, Ferrer A, Villamor N et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rates and disease eradication. Clin. Cancer Res. 14, 155-161 (2008).
12. Rawstron AC, Kennedy B, Evans PA et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98, 29-35 (2001).
13. Bottcher S, Fischer K, Stilgenbauer S et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. Blood 112, a326 (2008) (Abstract).
14. Kwok M, Rawstron AC, Varghese A et al. Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (CLL) that is independent of the type or line of therapy. Blood 114, a540 (2009) (Abstract).
15. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 111, 5446-5456 (2008).
16. Binet JL, Lepoprier M, Dighiero G et al. A clinical staging system for chronic lymphocytic leukemia: Prognostic significance. Cancer 40, 855 (1977).
17. Molica S, Levato D, Dattilo A. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival. Haematologica 84, 1094-1099 (1999).
18. Muntanola A, Bosch F, Arguis P et al. Abdominal computer tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J. Clin. Oncol. 25, 1576-1580 (2007).
19. Nabhan C, Shanafelt TD, Kay NE. Controversies in the front-line management of chronic lymphocytic leukemia. Leuk. Res. 32, 679-688 (2008).
20. Rozman C, Montserrat E, Rodriguez-Fernandez JM et al. Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 64, 642-648 (1984).
21. Han T, Barcos M, Emrich L et al. Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: Correlations with clinical, immunologic, phenotypic, and cytogenetic data. J. Clin. Oncol. 2, 562-570 (1984).
22. Melo JV, Catovsky D, Gregory WM et al. The relationship between chronic lymphocytic leukaemia and prolymphocyticleukaemia. IV. Analysis of survival and prognostic features. Br. J. Haematol. 65, 23-29 (1987).
23. Nowakowski GS, Hoyer JD, Shanafelt TD et al. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J. Clin. Oncol. 27(11), 1844-1849 (2009).
24. Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: The importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br. J. Haematol. 72, 141-149 (1989).
25. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 60(11), 2712-2716 (1987).
26. Montserrat E, Sanchez-Bisono J, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br. J. Haematol. 62(3), 567-575 (1986).
27. Bergmann MA, Eichhorst BF, Busch R et al. Prospective evaluation of prognostic parameters in early stage chronic lymphocytic leukemia (CLL): Results of the CLL1-protocol of the German CLL study group (GCLLSG). Blood 110(11), 193a (2007) (Abstract 625).
28. Hallek M, Wanders L, Ostwald M et al. Serum b(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk. Lymphoma 22, 439-447 (1996).
29. Molica S, Levato D, Cascavilla N et al. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and β2-microglobulin in B-cell chronic lymphocytic leukemia. Eur. J. Haematol. 62, 117-122 (1999).
30. Gentile M, Cutrona G, Neri A et al. Predictive value of β2-microglobulin (b2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 94, 887-888 (2009).
31. Simonsson B, Wibell L, Nilsson K. β2-microglobulin in chronic lymphocytic leukemia. Scand. J. Haematol. 24, 174-180 (1980).
32. Delgado J, Pratt G, Phillips N et al. β2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukemia if adjusted to glomerular filtration rate. Br. J. Haematol. 145, 801-805 (2009).
33. Keating M, Lerner S, Kantarjian H et al. The serum B2 microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 86, 606a (1995) (Abstract).
34. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4070-4078 (2005).
35. Wierda WG, O'Brien S, Wang X et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109, 4679-4685 (2007).
36. Hallek M, Langenmayer I, Nerl C et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progression in early, non-smoldering chronic lymphocytic leukemia. Blood 93, 1732-1737 (1999).
37. Magnac C, Porcher R, Davi F et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 17, 133-137 (2003).
38. Matthews C, Catherwood MA, Morris TC et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur. J. Haematol. 77, 309-317 (2006).
39. Wierda WG, O'Brien S, Wang X et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J. Clin. Oncol. 27, 1637-1643 (2009).
40. Shanafelt TD, Jenkins G, Timothy G et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 115, 363-372 (2009).
41. Swerdlow S. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (4th Edition). Swerdlow S (Ed.). WHO, Geneva, Switzerland (2008).
42. Juliusson G, Oscier DG, Fitchett M et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N. Engl. J. Med. 323, 720-724 (1990).
43. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910-1916 (2000).
44. Dewald GW, Brockman SR, Paternoster SF et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: Correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 121, 287-295 (2003).
45. Shanafelt TD, Witzig TE, Fink SR et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early stage chronic lymphocytic leukemia. J. Clin. Oncol. 24, 4634-4641 (2006).
46. Rosenwald A, Chuang EY, Davis RE et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104, 1428-1434 (2004).
47. Catovsky D, Richards S, Oscier D et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomized controlled trial. Lancet 370(9583), 230-239 (2007).
48. Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 21(1), 12-17 (2007).
49. Tam CS, Shanafelt TD, Wierda WG et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The MD Anderson and Mayo Clinic experience. Blood 114(5), 957-964 (2009).
50. Zenz T, Benner A, Dohner H et al. Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway. Cell Cycle 7, 3810-3814 (2008).
51. Dohner H, Stilgenbauer S, James MR et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89, 2516-2522 (1997).
52. Neilson JR, Auer R, White D et al. Deletions at 11q identify a subgroup of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 11(11), 1229-1232 (1997).
53. Tsimberidou AM, Tam C, Abruzzo LV et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2), 373-380 (2009).
54. Finn WG, Thangavelu M, Yelavarthi KK et al. Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am. J. Clin. Pathol. 105, 458-467 (1996).
55. Witzig TE, Borell TJ, Herath J et al. Detection of trisomy 12 by FISH in untreated B-chronic lymphocytic leukemia: Correlation with stage and CD20 antigen expression intensity. Leuk. Lymphoma 14(5-6), 447-451 (1994).
56. Tam CS, Otero-Palacios J, Abruzzo LV et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: A study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br. J. Haematol. 141(1), 36-40 (2008).
57. Stilgenbauer S, Sander S, Bullinger L et al. Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 92, 1242-1245 (2007).
58. Dicker F, Schnittger S, Haferlach T et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 108, 3152-3160 (2006).
59. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 408, 307-310 (2000).
60. Zenz T, Krober A, Scherer K et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 112, 3322-3329 (2008).
61. Gonzalez D, Martinez P, Wade R et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: Results from the LRF CLL4 trial. J. Clin. Oncol. 29, 2223-2229 (2011).
62. Dicker F, Herholz H, Schnittger S et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23, 117-124 (2009).
63. Zenz T, Eichhorst B, Busch R et al. TP53 mutation and survival in chronic lymphocytic leukemia. J. Clin. Oncol. 28, 4473-4479 (2010).
64. Best OG, Gardiner AC, Davis ZA et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IgHV genes have stable disease. Leukemia 23(1), 212-214 (2009).
65. Hamblin TJ, Davis Z, Gardiner A et al. Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848-1854 (1999).
66. Damle JN, Wasil T, Fais F et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840-1847 (1999).
67. Oscier DG, Gardiner AC, Mould SJ et al. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100, 1177-1184 (2002).
68. Krober A, Seiler T, Leupolt E. IgHV mutated and unmutated B-CLL tumors show distinct genetic aberrations patterns. Blood 96, 3609a (2000) (Abstract).
69. Maloum K, Davi F, Merle-Beral H et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 96, 377-379 (2000).
70. Krober A, Seiler T, Benner A et al. v(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100, 1410-1416 (2002).
71. Oscier D, Wade R, Davis Z et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 95, 1705-1712 (2010).
72. Haferlach C, Dicker F, Weiss T. Toward a comprehensive prognostic scoring systemin chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes Cancer 49(9), 851-859 (2010).
73. Tobin G, Thunberg U, Johnson A et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vl2-14 gene use and homologous CDR3s: Implicating recognition of a common antigen epitope. Blood 101, 4952-4957 (2003).
74. Thorselius M, Krober A, Murray F et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 107, 2889-2894 (2006).
75. Alessio M, Roggero S, Funaro A et al. CD38 molecule: Structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. J. Immunol. 145, 878-884 (1990).
76. Schuber F, Lund FE. Structure and enzymology of ADP-ribosylcyclases: Conserved enzymes that produce multiple calcium mobilizing metabolites. Curr. Mol. Med. 4, 249-261 (2004).
77. Lee HC. Physiological functions of cyclic ADP ribose and NAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol. 41, 317-345 (2001).
78. Chevallier P, Penther D, Avet-Loiseau H et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br. J. Haematol. 116, 142-150 (2002).
79. Ibrahim S, Keating M, Do KA et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98, 181-186 (2001).
80. Ghia P, Guida G, Stella S et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101, 1262-1269 (2003).
81. Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99, 1023-1029 (2002).
82. Hamblin TJ, Orchard JA, Gardiner A et al. Immunoglobulin V genes and CD38 expression in CLL. Blood 95, 2455-2457 (2000).
83. Jelinek DF, Tschumper RC, Geyer SM et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br. J. Haematol. 115, 854-861 (2001).
84. Del Poeta G, Maurillo L, Venditti A et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98, 2633-2639 (2001).
85. Patten PE, Buggins AG, Richards J et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111, 5173-5181 (2008).
86. Rassenti LZ, Jain S, Keating MJ et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112, 1923-1930 (2008).
87. Mustelin T, Tasken K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem. J. 371, 15-27 (2003).
88. Schroers R, Griesinger F, Trumper L et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 19, 750-758 (2005).
89. Orchard JA, Ibbotson RE, Davis Z et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363, 105-111 (2004).
90. Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348, 1764-1775 (2003).
91. Durig J, Nuckel H, Cremer M et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17, 2426-2434 (2003).
92. Rassenti LZ, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 351, 893-901 (2004).
93. Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101, 4944-4951 (2003).
94. Admirand JH, Knoblock RJ, Coombes KR et al. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod. Pathol. 23(11), 1518-1523 (2010).
95. Kern W, Dicker F, Schnittger S et al. Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. Cytometry Part B: Clin. Cytometry 76B(6), 385-393 (2009).
96. Kern W, Dicker F, Schnittger S et al. Correlation of flow cytometrically determined expression of ZAP-70 using two different antibodies with IgVH mutation status and cytogenetics in 539 patients with chronic lymphocytic leukemia. Blood 108, 495 (2006) (ASH Annual Meeting Abstracts).
97. Doubek M, Mayer J, Obrtlikova P et al. Modern and conventional prognostic markers of chronic lymphocytic leukemia (CLL) in the everyday hematological practice. Eur. J. Haematol. 87(2), 130-137 (2011
98. Tam CS, Keating MJ, Tsimberidou AM et al. The clinical usefulness of novel prognostic factors in CLL: A study of 477 patients with low-risk (non-11q, non-17p) FISH and known IGVH mutation status. Blood 110, 3079 (2007) (ASH Annual Meeting Abstracts).
99. Lin KI, Tam CS, Keating MJ et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113, 3168-3171 (2009).